A Study to Investigate LYL797 in Adults With Solid Tumors

Inclusion Criteria

• ≥ 18 years of age at time of informed consent
• Confirmation of ROR1 expression from a pretreatment tumor sample
• Histologically confirmed TNBC or NSCLC that is relapsed or refractory, metastatic or locally advanced and unresectable
• Platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary peritoneal cancer.
• Endometrial cancer.
• Measurable disease including a target lesion and an additional lesion for biopsy
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Adequate organ and marrow function
• Women of childbearing potential must have a negative pregnancy test at screening
• All participants must agree to practice highly effective methods of contraception

Exclusion Criteria

• Prior treatment with any adoptive T-cell therapy or other anti-ROR1 therapy
• Prior solid organ transplantation
• Active, untreated brain metastasis or leptomeningeal disease; however, stable, treated brain metastases are allowed
• Untreated or active infection at the time of screening or leukapheresis
• HIV-positive, HTLV-1-positive, active acute HAV, acute or chronic HBV or HCV, or active tuberculosis
• Impaired cardiac function or clinically significant cardiac disease
• Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures (once monthly or more frequent), or lymphangitis carcinomatosis
• History of interstitial pneumonitis or pulmonary fibrosis.
• Systemic corticosteroids or other immunosuppressive medications within 14 days of leukapheresis
• Pregnant or lactating/nursing women